Structure via PubChem · Public domain (PubChem)
mosapride
Sign in to saveMosapride is a gastroprokinetic agent that acts as a selective 5HT4 agonist. The major active metabolite of mosapride, known as M1, additionally acts as a 5HT3 antagonist, which accelerates emptying throughout the whole of the gastrointestinal tract in humans, and is used for the treatment of gastritis, gastroesophageal reflux disease, functional dyspepsia and irritable bowel syndrome. It is recommended to be taken on an empty stomach (i.e. at least one hour before food or two hours after food).
Chemical data
- Formula
- C21H25ClFN3O3
- Molecular weight
- 421.9 g/mol
- IUPAC name
- 4-amino-5-chloro-2-ethoxy-N-[[4-[(4-fluorophenyl)methyl]morpholin-2-yl]methyl]benzamide
- SMILES
- CCOC1=CC(=C(C=C1C(=O)NCC2CN(CCO2)CC3=CC=C(C=C3)F)Cl)N
- InChIKey
- YPELFRMCRYSPKZ-UHFFFAOYSA-N
- XLogP
- 2.8
- Polar surface area
- 76.8 Ų
- H-bond donors
- 2
- H-bond acceptors
- 6
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Phase 3
- Molecule type
- Small molecule
- Indications
- irritable bowel syndrome, Constipation, gastritis, Diarrhea
via ChEMBL · EBI
Research
482 papers- Mosapride in gastrointestinal disorders.Drugs · 2008
- Mosapride-Induced Movement Disorders.Journal of movement disorders · 2022
- Mosapride treatment for functional dyspepsia: a meta-analysis.Journal of gastroenterology and hepatology · 2015
- Mosapride stimulates human 5-HT(4)-serotonin receptors in the heart.Naunyn-Schmiedeberg's archives of pharmacology · 2024
- Efficacy of mosapride plus proton pump inhibitors for treatment of gastroesophageal reflux disease: a systematic review.World journal of gastroenterology · 2013
via PubMed
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 421.156848
- Has use
- medication
Show 4 more facts
- chemical formula
- C₂₁H₂₅ClFN₃O₃
- canonical SMILES
- CCOC1=CC(=C(C=C1C(=O)NCC2CN(CCO2)CC3=CC=C(C=C3)F)Cl)N
- subject has role
- serotonin receptor agonists
- Commons category
- Mosapride
via Wikidata · CC0
~2 min read
Encyclopedic overview
1 sectionsContents
- References
Mosapride is a gastroprokinetic agent that acts as a selective 5HT4 agonist. The major active metabolite of mosapride, known as M1, additionally acts as a 5HT3 antagonist, which accelerates emptying throughout the whole of the gastrointestinal tract in humans, and is used for the treatment of gastritis, gastroesophageal reflux disease, functional dyspepsia and irritable bowel syndrome. It is recommended to be taken on an empty stomach (i.e. at least one hour before food or two hours after food).
In addition to its prokinetic properties, mosapride also exerts anti-inflammatory effects on the gastrointestinal tract which may contribute to some of its therapeutic effects. Mosapride also promotes neurogenesis in the gastrointestinal tract which may prove useful in certain bowel disorders. The neurogenesis is due to mosapride's effect on the 5-HT4 receptor where it acts as an agonist.
Excerpted from Wikipedia’s “mosapride” article, available under the CC BY-SA 4.0 licence.